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Introduction 121 Antidepressant medications are a first-line treatment option for moderate to severe mood 122 and anxiety disorders, yet some studies suggest that long-term use may be associated with an 123 increased risk for cardiovascular disease [1] [2] [3] . We recently reported that use of tricyclic 124 antidepressants (TCA's) is associated with a two-fold higher prevalence in coronary heart 125 disease (CHD), relative to non-use in a cross-sectional analysis on the Brazilian longitudinal 126 study of adult health (ELSA-Brasil) [4] . Although no associations were observed for the SSRI 127 class, antidepressant use in Brazil is lower than in high-income countries. With the exception 128 of sertraline and fluoxetine, SSRIs are not freely dispensed in public health pharmacies, as are 129 tricyclics [5] . While TCA's are generally not recommended for depressed patients who have 130 CHD [6] , the effects of the selective serotonin reuptake inhibitor (SSRI) class of 131 antidepressants remain unclear. In the present study, we examined the associations of 132 specific medications in the SSRI class with resting state heart rate (HR) and heart rate 133 variability (HRV), two psychophysiological indicators of health and wellbeing shown to 134 predict future mortality [7] . The heart is under tonic inhibitory control by the 135 parasympathetic (vagal) nervous system when at rest [8] , and both HR and HRV under resting 136 conditions may reflect vagally mediated cardiac activity. It is noted however, that HRV is a 137 more specific measure of vagal activity [9, 10] , while HR may also include sympathetic input. 138
139
While the SSRIs are considered to be the safest class of antidepressant medications for use in 140 cardiac patients [e.g. 11], they have also been reported to reduce HRV in depressed patients, 141 compared to those not receiving an antidepressant, and to normal controls [12] . A variety of 142 mechanisms have been proposed to contribute to the development of cardiovascular disease 143 in users of antidepressants including SSRIs. These include increased HR, orthostatic 144 hypotension, slowing of ventricular cardiac conduction, and antiarrhythmic activity [13] . 145
Another strong candidate for increased risk of cardiovascular disease is impairment in vagal 146 function [7] . Vagal function plays an important regulatory role over a variety of allostatic 147 Participants were asked to abstain from caffeine, alcohol and physical activity for at least 12 214 hours before assessments. Participants were asked to bring all of the prescription and over-215 the-counter pill bottles to an interview for review by the interviewer. Individuals taking one 216 selective serotonin reuptake inhibitor (SSRI) medication continuously over the past two 217 weeks were classified as users, and grouped according to the specific antidepressant they 218 were taking. Selective serotonin reuptake inhibitors were defined using the Anatomical 219 Covariates included sociodemographic factors (age; sex; level of education; race), 242 cardiovascular risk factors (smoking; body mass index; hypertension; diabetes; and 243 dyslipidemia), established heart disease and associated medications, physical inactivity and 244 psychiatric morbidity. Level of education was entered as two dummy coded variables (less 245 than high school: yes versus no; completed high school: yes versus no), while race was 246 entered as a categorical variable indicating whether participants were non-White (yes versus 247 no). Smoking status was indicated if participants were current smokers (current versus 248 past/never) and body mass index (BMI) was determined as follows: weight in kilograms 249 divided by height in meters squared. Hypertension was defined as a systolic blood pressure 250 ≥140 mmHg, a diastolic blood pressure ≥90 mmHg, or use of antihypertensive medications. 251
Diabetes was defined as self-reported or fasting blood glucose level ≥126 mg/dL, a 2-hour 252 oral glucose tolerance test glucose level ≥200 mg/dL, or a glycated hemoglobin level ≥6.5%. 253
Dyslipidemia was defined as an LDL cholesterol level ≥130 mg/dL or use of lipid-lowering 254 medication. Blood samples were collected after a 12-hour overnight fast and medication use 255 was determined on the basis of pill bottle review. Established heart disease was determined 256 through a prior history of a physician-diagnosed myocardial infarction, a prior percutaneous 257 coronary intervention including balloon angioplasty with or without stent placement, a prior 258 surgical revascularization consisting of either arterial or venous grafts. Complementing this 259 self-report information, major Q wave abnormalities (yes versus no) on the 12-lead ECG were 260 also entered into analyses as a covariate. Physical activity was measured using the 261
International Physical Activity Questionnaire [28] and categorized according to low activity 262 versus moderate or high activity, as determined using scoring guidelines. Psychiatric to adjust findings for the above covariates. These techniques involve calculating a single 277 propensity score on the basis of entered covariates for each participant that relates to the 278 probability that the participant belongs to the same distribution (i.e. antidepressant 279 grouping). Two propensity analytic methods were employed: PSW and PSM. While PSW 280 involves entering the propensity score into regression models, PSM involves selecting 281 comparison participants (non-users of antidepressants) to match other groups on propensity 282 scores. PSW was carried out using the 'twang' and 'survey' packages, while PSM was 283 conducted using the 'MatchIt' package in the R statistical environment. Details on how to 284 implement these procedures have been described previously [23, 31] . PSM was conducted as 285 a sensitivity analysis, allowing the effective sample size of medication groupings to be 286 
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Participant Characteristics
education, ethnicity, LDL cholesterol, and psychiatric morbidity, highlighting the importance 303 of propensity score techniques to better control for the associations between these variables 304 and HR, and HRV. It is possible for instance, that the differences in confounding variables may 305 account for differences between groups on HR and HRV. The unadjusted results for HR and 306 HRV are also reported in Table 1 in both PSW and PSM, relative to non-users, findings associated with small to moderate effect 324 size (dark grey shaded cells in Table 2 ). 325
326
Specificity Analyses 327
Additional PSW analysis was conducted to compare each SSRI medication after dropping 328 controls from the analyses. This allowed for the effective sample size of medication groupings 329 to be increased and for a higher-powered, head-to-head comparison between SSRI 330 medications to be conducted. After application of PSW, effective sample sizes were as follows: 331 escitalopram, n=36; citalopram=73; fluoxetine=57; paroxetine=84; sertraline=122. Analyses 332 revealed significant differences on HR (F(4,435) This study examined and compared the impact of specific antidepressants within the SSRI 343 class on resting-state HR and HRV. This is an important issue as chronic alterations of HR and 344 HRV by SSRI antidepressants may lead to morbidity from a host of conditions and diseases, 345 and mortality [7, 35] . Major findings from this study suggest that: 1) all users of SSRIs -except 346 fluoxetine -display alterations in HR or HRV relative to non-users; findings for HRV appeared 347 to be more robust and consistent for HRV, than those for HR, 2) users of citalopram display a 348 interesting to note that our earlier study [15] reported that tricyclic antidepressants and 389
SNRIs were associated with moderate to large increases in HR and decreases in HRV. By 390 contrast, paroxetine in the present study is associated with small to moderate reductions in 391 HRV. These effect sizes are presumably smaller than those we observed for tricyclic and SNRI 392 medications, as some participants on paroxetine may have been prescribed dosages less than 393 40mg/day. It is also notable that while SNRIs and tricyclic antidepressants may also lead to 394 tachycardia in addition to reductions in HRV, users of paroxetine in the present study only 395 exhibited decreases in HRV, not increases in HR (relative to non-users). 396
397
In contrast to paroxetine, fluoxetine was the only antidepressant that was not associated with 398 significant alterations in cardiac activity. Fluoxetine is generally considered a safe medication 399 for patients with cardiovascular disease. An early study [43] on depressed elderly patients 400 with pre-existing cardiovascular disease reported that fluoxetine decreased HR by 6% (n=27), 401 while nortriptiline, a tricyclic antidepressant, was associated with a 9% increase (n=52). This 
